Inclusion Criteria:  The following criteria must be met for a child to be enrolled in the study:  Age 4 to 40 years male and female Amblyopia associated with strabismus, anisometropia, or both (previously treated or untreated) Must have refractive error correction (based on a cycloplegic refraction completed within the last 7 months) Spectacle correction meeting the above criteria must be worn For at least 16 weeks OR until distance VA stability is documented (defined as <0.1 logMAR change by the same testing method measured on 2 consecutive exams at least 8 weeks apart).  VA, measured in each eye without cycloplegia in current spectacle correction using the Lea symbol per ATS VA protocol for children < 7 years and the EETDRS VA protocol for children ≥ 7 years on a study-approved device displaying single surrounded optotypes, as follows:  Visual acuity in the amblyopic eye <1.0 logMAR (20/200) Best-corrected dominant-eye VA <0.2 Interocular difference ≥ 2 logMAR lines Heterotropia with a near deviation of <5∆ (measured by SPCT) in habitual correction (Angles of ocular deviation >4∆ are not allowed because large magnitudes of the deviation would compromise successful alignment of the dichoptic stimuli.) Passing a dedicated 10 min in-clinic performance ability test to assure suitable eye tracking performance (validity of eye tracking data >90% and successful calibration process).  7. Subjects and families eligible for clinic visits over duration of study.  8. Subject in general good health and able, as per investigator decision, to comply with study visits and protocol procedures and wear refractive correction and has access to wireless internet at home which is able to support the CureSight treatment (loaned by sponsor).  9. Signed and dated informed consent form.  10. Parent and participant understand and are willing to comply with study procedures and will be available for the duration of the study.  Exclusion Criteria:  Myopia greater than -6.00 D. spherical equivalent in either eye. Known skin reactions to patch or bandage adhesives. Severe developmental delay that would interfere with treatment or evaluation (in the opinion of the investigator). Any condition that might interfere with eye tracking, such as ptosis Any reported anatomic ocular anomaly (e.g., small lens opacity, myelinated nerve fiber layer). Previous intraocular or refractive surgery. Heterophoria with a total near deviation of ≥10Δ (measured by PACT